Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors

被引：14

作者：

Dong, Yuhong ^{[1
]}

Hu, Hao ^{[1
]}

Sun, Yuwei ^{[1
]}

Qin, Mingze ^{[1
]}

Gong, Ping ^{[1
]}

Hou, Yunlei ^{[1
]}

Zhao, Yanfang ^{[1
]}

机构：

[1] Shenyang Pharmaceut Univ, Key Lab Struct Based Drug Design & Discovery, Minist Educ, 103 Wenhua Rd, Shenyang 110016, Peoples R China

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2020年 / 30卷 / 23期

基金：

中国国家自然科学基金;

关键词：

c-Met; HDAC; Design; Synthesis; Antitumor activity; HISTONE DEACETYLASE INHIBITORS; 4-PHENOXYQUINOLINE DERIVATIVES; MULTITARGET THERAPEUTICS; MULTIPLE LIGANDS; CANCER; MET; POLYPHARMACOLOGY; RECEPTOR; MOIETY;

D O I：

10.1016/j.bmcl.2020.127610

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

In this work three novel series of c-Met/HDAC bifunctional inhibitors were designed and synthesized by merging pharmacophores of c-Met and HDAC inhibitors. The most potent compound 11j inhibited c-Met kinase and HDAC1 with IC50 values of 21.44 and 45.22 nM, respectively. In addition, 11j showed efficient antiproliferative activities against both MCF-7 and A549 cells with greater potency than the reference drug SAHA and Cabozantinib. This work may lay the foundation for developing novel dual c-Met/HDAC inhibitors as potential anticancer therapeutics.

引用

页数：7

共 29 条

[1] Polypharmacology: Challenges and Opportunities in Drug Discovery [J].

Anighoro, Andrew ;

Bajorath, Juergen ;

Rastelli, Giulio .

JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (19) :7874-7887

[2]

[Anonymous], 2019, PRELIMINARY EFFICACY

[3] Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders [J].

Bawa, Priya ;

Pradeep, Priyamvada ;

Kumar, Pradeep ;

Choonara, Yahya E. ;

Modi, Girish ;

Pillay, Viness .

DRUG DISCOVERY TODAY, 2016, 21 (12) :1886-1914

[4]

Bolognesi ML, 2013, CURR MED CHEM, V20, P1639

[5] Phase 1 Study of Oral Abexinostat, a Histone Deacetylase Inhibitor, in Combination With Doxorubicin in Patients With Metastatic Sarcoma [J].

Choy, Edwin ;

Flamand, Yael ;

Balasubramanian, Sriram ;

Butrynski, James E. ;

Harmon, David C. ;

George, Suzanne ;

Cote, Gregory M. ;

Wagner, Andrew J. ;

Morgan, Jeffrey A. ;

Sirisawad, Mint ;

Mani, Chitra ;

Hornicek, Francis J. ;

Duan, Zhenfeng ;

Demetri, George D. .

CANCER, 2015, 121 (08) :1223-1230

[6] Structural and Molecular Insight into Resistance Mechanisms of First Generation cMET Inhibitors [J].

Collie, Gavin W. ;

Koh, Cheryl M. ;

O'Neill, Daniel J. ;

Stubbs, Christopher J. ;

Khurana, Puneet ;

Eddershaw, Alice ;

Snijder, Arjan ;

Mauritzson, Fredrik ;

Barlind, Louise ;

Dale, Ian L. ;

Shaw, Joseph ;

Phillips, Christopher ;

Hennessy, Edward J. ;

Cheung, Tony ;

Narvaez, Ana J. .

ACS MEDICINAL CHEMISTRY LETTERS, 2019, 10 (09) :1322-1327

[7] Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress [J].

Cui, J. Jean .

JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (11) :4427-4453

[8] Design, synthesis, and biological evaluation of potent c-Met inhibitors [J].

D'Angelo, Noel D. ;

Bellon, Steven F. ;

Booker, Shon K. ;

Cheng, Yuan ;

Coxon, Angela ;

Dominguez, Celia ;

Fellows, Ingrid ;

Hoffman, Douglas ;

Hungate, Randall ;

Kaplan-Lefko, Paula ;

Lee, Matthew R. ;

Li, Chun ;

Liu, Longbin ;

Rainbeau, Elizabeth ;

Reider, Paul J. ;

Rex, Karen ;

Siegmund, Aaron ;

Sun, Yaxiong ;

Tasker, Andrew S. ;

Xi, Ning ;

Xu, Shimin ;

Yang, Yajing ;

Zhang, Yihong ;

Burgess, Teresa L. ;

Dussault, Isabelle ;

Kim, Tae-Seong .

JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (18) :5766-5779

[9] Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders [J].

Falkenberg, Katrina J. ;

Johnstone, Ricky W. .

NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (09) :673-691

[10] HDAC inhibitors still need a home run, despite recent approval [J].

Guha, Malini .

NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (04) :226-227

← 1 2 3 →